New publication addresses PTAB concerns for pharma, biotech

Biosimilar News  •  PTAB + IPR

Goodwin Procter announced today the publication of Pharmaceuticals at the Patent Trial and Appeal Board, a guide that addresses proactive measures for pharmaceutical companies involved in litigation before the PTAB. The guide explores key statistics and case studies that reveal how the PTAB is handling pharmaceutical matters and lays out practical advice for companies engaged in or considering PTAB actions.  The guide’s dedicates a section to biosimilars, including a discussion of the pros and cons of filing inter partes reviews in biosimilars patent litigation.

To request a copy of the guide, please click here.

 

 

Download PDF

Tagged with 

Comments are closed.